about
Design and pre-clinical evaluation of a universal HIV-1 vaccineProtective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccineImmunoinformatics comes of ageThe emergence of HIV/AIDS in the Americas and beyondThe effect of recombination on the reconstruction of ancestral sequencesFastML: a web server for probabilistic reconstruction of ancestral sequencesComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesEvolution of proviral gp120 over the first year of HIV-1 subtype C infectionClade, Country and Region-specific HIV-1 Vaccines: Are they necessary?The role of Fc-FcγR interactions in IgG-mediated microbial neutralizationAssociation of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysisAntibodies in HIV-1 vaccine development and therapyA global approach to HIV-1 vaccine developmentADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challengeDivergent and convergent evolution after a common-source outbreak of hepatitis C virusThe hepatitis C sequence database in Los AlamosAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesRNA virus genomics: a world of possibilitiesDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceClinical significance of HIV-1 coreceptor usage.Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccineHeterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsAn evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1Viral population estimation using pyrosequencingAncestral ReconstructionMapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step studyIn silico comparison of Iranian HIV -1 envelop glycoprotein with five nearby countriesEpigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus VaccineReconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 ProteinsHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesA consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza virusesSurvivors Remorse: antibody-mediated protection against HIV-1.20 years since human immunodeficiency virus discovery: considerations for the next decade.Recombinant viruses and early global HIV-1 epidemicCTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentMolecular epidemiology of HIV in two highly endemic areas of northeastern South Africa.An integrated map of HIV genome-wide variation from a population perspective.
P2860
Q21092234-3869FE23-D8D4-4D21-975A-6E97356EA0C7Q21131325-3573CC57-4ADD-46DC-A191-ECEDF569E557Q21145682-EBE3457D-CD04-4965-AFDD-96EFA38EB283Q22248090-D1BBB753-B1C1-49FE-BB2E-A377F656DC46Q22305973-9A1942C3-86C2-430B-8A4F-B4A483D73C15Q24498093-1597BA99-5BE1-4D45-8560-93B6542C578FQ24561905-E1EE2B56-3E6E-43ED-AD94-718B35F9A6ACQ24653373-AE00EB28-F11C-4338-8783-AA8011C087F2Q24803275-72BE95AC-4733-42E6-8A94-C80B99DCAF07Q26797466-4D9148E2-ECF7-4C8D-9302-D069A2A1DB79Q27000959-002C4803-E1D2-4A46-A2A8-23E4A76631F5Q27011574-B724F694-44C6-4C2D-B35A-984640224421Q27024614-7AF07B7C-543E-415D-BC91-4FCADD7EDDE3Q27342615-24D95118-DA78-4DB5-B9DB-CD0CCF7E307EQ27485216-56D71C4F-09E1-4D5E-859E-7198989ABBCBQ27485377-0A5C03C6-A876-4E4F-BB6A-DF5352531957Q27489000-4ED2CF05-E34F-4254-870E-C815FEA93D11Q27489430-ECA285A1-DEC2-41CB-8853-3C37F605B1F1Q27654848-F2D3B5B9-04A8-4A49-A7A5-AD3A65AA54B6Q27664086-AE0589DE-5114-4BDA-90E9-DC8666F02492Q27691426-2A9002A7-1534-4130-BF9E-65E929F12F0DQ28387636-F697D75F-7134-4C47-B139-7444CBDBFE80Q28394899-9FA29F83-C807-4AE1-A833-6266173890E0Q28471994-B926F33D-FD92-4083-85E3-E202D2EEB840Q28472641-358CBB99-FC30-49FC-B089-647D72D3A75BQ28596371-D1F3F648-F03A-4925-A4AD-460F71E1465CQ28743767-CA09EAAD-A39E-45A0-9EFD-3E8CFB2A25D9Q28817796-F6EC5E55-0C21-47A3-B7E6-6667F5AD7D68Q28822525-FE4354D1-0F97-4411-9C4F-C4F2C87CE246Q29010789-402A0E06-35EB-4C71-A81A-0EAD5C90C3BDQ29307502-89EB6491-68E8-4800-A0BA-3A98E911A024Q29619015-E62DD9D4-0AD8-4185-BD11-C892ED9D429FQ30228657-D545EDBB-6386-4E47-A725-8F419B486AD0Q30238730-37BD77FA-261A-48C9-8980-516FC58FBE2EQ30332600-9D25D502-C636-4592-8F97-9D6E2FA3A048Q30342738-2D244EC9-4A46-4C9C-8B75-69D4339FE8ABQ30353953-B0DFA57A-C6C5-4145-BD5F-77C79C0F6F11Q30355260-BA298E54-815B-4E16-B111-C39F115270E9Q30357556-2EC3EEA9-A523-4636-BEF6-E95D865230AFQ30373040-A712E990-EA9D-46B7-9039-3ACD85521FCB
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Diversity considerations in HIV-1 vaccine selection.
@ast
Diversity considerations in HIV-1 vaccine selection.
@en
Diversity considerations in HIV-1 vaccine selection.
@nl
type
label
Diversity considerations in HIV-1 vaccine selection.
@ast
Diversity considerations in HIV-1 vaccine selection.
@en
Diversity considerations in HIV-1 vaccine selection.
@nl
prefLabel
Diversity considerations in HIV-1 vaccine selection.
@ast
Diversity considerations in HIV-1 vaccine selection.
@en
Diversity considerations in HIV-1 vaccine selection.
@nl
P2093
P50
P356
P1433
P1476
Diversity considerations in HIV-1 vaccine selection.
@en
P2093
Brian Gaschen
Dorothy Lang
Jesse Taylor
Karina Yusim
Tanmoy Bhattacharya
Vladimir Novitsky
P304
P356
10.1126/SCIENCE.1070441
P407
P577
2002-06-01T00:00:00Z